Fate Therapeutics (FRA:F6T) Cyclically Adjusted FCF per Share: €-1.17 (As of Jun. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

FRA:F6T Fate Therapeutics Inc FRA:F6T
33 GF Score
Price €2.11
GF Value €0.65
Valuation Significantly Overvalued
! 7 Warning Signs
View Full Analysis

What is Fate Therapeutics Cyclically Adjusted FCF per Share?

Fate Therapeutics FRA:F6T -7.79% 33 Cyclically Adjusted FCF per Share is €-1.17 as of Jun. 2026. GuruFocus rates FRA:F6T with a GF Score™ of 33/100 and a GF Value™ of €0.65 (Significantly Overvalued). The stock has 7 warning signs investors should review.

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted FCF per Share and the Cyclically Adjusted Price-to-FCF. The Cyclically Adjusted FCF per Share is the average of the inflation adjusted Free Cash Flow per Share of a company over the past 10 years.

Fate Therapeutics's adjusted free cash flow per share for the three months ended in Jun. 2026 was €-0.170. Add all the adjusted free cash flow per share for the past 10 years together and divide the count will get our Cyclically Adjusted FCF per Share, which is €-1.17 for the trailing ten years ended in Jun. 2026.

During the past 3 years, the average Cyclically Adjusted FCF Growth Rate was -1.80% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the Cyclically Adjusted FCF Growth Rate using Cyclically Adjusted FCF per Share data.

During the past 13 years, the highest 3-Year average Cyclically Adjusted FCF Growth Rate of Fate Therapeutics was -1.80% per year. The lowest was -1.80% per year. And the median was -1.80% per year.

As of today (2026-08-16), Fate Therapeutics's current stock price is €2.106. Fate Therapeutics's Cyclically Adjusted FCF per Share for the quarter that ended in Jun. 2026 was €-1.17. Fate Therapeutics's Cyclically Adjusted Price-to-FCF of today is .


Fate Therapeutics  (FRA:F6T) Cyclically Adjusted FCF per Share Explanation

If a company grows much fast than inflation, Cyclically Adjusted FCF per Share may underestimate the company's free cash flow. Cyclically Adjusted Price-to-FCF can seem to be too high even the actual Price-to-Free-Cash-Flow is low.

For the Cyclically Adjusted Price-to-FCF, the free cash flow per share of the past 10 years are inflation-adjusted and averaged. The result is used for P/FCF calculation. Since it looks at the average over the last 10 years, the Cyclically Adjusted Price-to-FCF is also called CAPFCF Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Price-to-FCF. The Cyclically Adjusted FCF per Share is the average of the inflation adjusted free cash flow per share of a company over the past 10 years.


Be Aware

Cyclically Adjusted Price-to-FCF works better for cyclical companies. It gives you a better idea on the company's real free cash flow value.


Fate Therapeutics Cyclically Adjusted FCF per Share Related Terms


Fate Therapeutics Cyclically Adjusted FCF per Share Historical Data

* Premium members only.

The historical data trend for Fate Therapeutics's Cyclically Adjusted FCF per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Fate Therapeutics Cyclically Adjusted FCF per Share Chart

Fate Therapeutics Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Cyclically Adjusted FCF per Share
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.00 -1.33 -1.43 -1.38 -1.26

Fate Therapeutics Quarterly Data
Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26 Jun26
Cyclically Adjusted FCF per Share Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -1.18 -1.01 -1.26 -1.24 -1.17

FRA:F6T vs IMRX, NWBO, FHTX: Cyclically Adjusted FCF per Share Comparison

For the Biotechnology subindustry, Fate Therapeutics's Cyclically Adjusted Price-to-FCF, along with its competitors' market caps and Cyclically Adjusted Price-to-FCF data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Fate Therapeutics Cyclically Adjusted Price-to-FCF vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Fate Therapeutics's Cyclically Adjusted Price-to-FCF distribution charts can be found below:

* The bar in red indicates where Fate Therapeutics's Cyclically Adjusted Price-to-FCF falls into.


FRA:F6T
33GF Score
Fate Therapeutics Inc FRA:F6T
Cyclically Adjusted FCF per Share is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Fate Therapeutics Cyclically Adjusted FCF per Share Calculation

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted FCF per Share and the Cyclically Adjusted Price-to-FCF. The Cyclically Adjusted FCF per Share is the average of the inflation adjusted Free Cash Flow per Share of a company over the past 10 years.

What is Cyclically Adjusted FCF per Share? How do we calculate Cyclically Adjusted FCF per Share?

Cyclically Adjusted FCF per Share is the average of the inflation adjusted Free Cash Flow per Share of a company over the past 10 years. Let's use an example to explain.

If we want to calculate the Cyclically Adjusted FCF per Share of Wal-Mart (WMT) for Dec. 31, 2010, we need to have the inflation data and the free cash flow per share from 2001 through 2010.

We adjusted the 2001 free cash flow per share data with the total inflation from 2001 through 2010 to the equivalent free cash flow in 2010. If the total inflation from 2001 to 2010 is 40%, and Wal-Mart's free cash flow is $1 a share in 2001, then the 2001's equivalent free cash flow in 2010 is $1.4 a share. If Wal-Mart's free cash flow is $1 again in 2002, and the total inflation from 2002 through 2010 is 35%, then the equivalent 2002 free cash flow in 2010 is $1.35. So on and so forth, you get the equivalent free cash flow per share of past 10 years. Then you add them together and divided the sum by the count to get Cyclically Adjusted FCF per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.

For example, Fate Therapeutics's adjusted Free Cash Flow per Share data for the three months ended in Jun. 2026 was:

Adj_FreeCashFlowPerShare= Free Cash Flow per Share /CPI of Jun. 2026 (Change)*Current CPI (Jun. 2026)
=-0.17/333.9520*333.9520
=-0.170

Current CPI (Jun. 2026) = 333.9520.

Fate Therapeutics Quarterly Data

Free Cash Flow per Share CPI Adj_FreeCashFlowPerShare
201609 -0.210 241.428 -0.290
201612 -0.193 241.432 -0.267
201703 -0.172 243.801 -0.236
201706 -0.200 244.955 -0.273
201709 -0.205 246.819 -0.277
201712 -0.223 246.524 -0.302
201803 -0.196 249.554 -0.262
201806 -0.190 251.989 -0.252
201809 -0.068 252.439 -0.090
201812 -0.165 251.233 -0.219
201903 -0.262 254.202 -0.344
201906 -0.300 256.143 -0.391
201909 -0.286 256.759 -0.372
201912 -0.334 256.974 -0.434
202003 -0.331 258.115 -0.428
202006 0.428 257.797 0.554
202009 -0.310 260.280 -0.398
202012 -0.216 260.474 -0.277
202103 -0.279 264.877 -0.352
202106 -0.402 271.696 -0.494
202109 -0.429 274.310 -0.522
202112 -0.819 278.802 -0.981
202203 -0.704 287.504 -0.818
202206 -0.619 296.311 -0.698
202209 -0.663 296.808 -0.746
202212 -0.797 296.797 -0.897
202303 -0.305 301.836 -0.337
202306 -0.288 305.109 -0.315
202309 -0.369 307.789 -0.400
202312 -0.342 306.746 -0.372
202403 -0.304 312.332 -0.325
202406 -0.256 314.175 -0.272
202409 -0.229 315.301 -0.243
202412 -0.226 315.605 -0.239
202503 -0.274 319.799 -0.286
202506 -0.190 322.561 -0.197
202509 -0.190 324.800 -0.195
202512 -0.175 324.054 -0.180
202603 -0.224 330.213 -0.227
202606 -0.170 333.952 -0.170

Add all the adjusted free cash flow per share together and divide 10 will get our Cyclically Adjusted FCF per Share.

What does a Cyclically Adjusted FCF per Share of €-1.17 mean?
Fate Therapeutics (FRA:F6T) has a Cyclically Adjusted FCF per Share of €-1.17 as of Jun. 2026. Cyclically Adjusted FCF per Share represents the company's inflation-adjusted FCF per share over a 10-year period. View historical data on Fate Therapeutics and its competitors.
Is Fate Therapeutics' Cyclically Adjusted FCF per Share too high?
Fate Therapeutics' current Cyclically Adjusted FCF per Share is €-1.17. Overall, Fate Therapeutics has a GF Score™ of 33/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Fate Therapeutics' Cyclically Adjusted FCF per Share compare to IMRX and NWBO?
Fate Therapeutics' Cyclically Adjusted FCF per Share of €-1.17 can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Cyclically Adjusted FCF per Share for a Biotechnology company?
A good Cyclically Adjusted FCF per Share depends on the Biotechnology industry context. However, Cyclically Adjusted FCF per Share should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Cyclically Adjusted FCF per Share mean?
A high Cyclically Adjusted FCF per Share can signal that a stock is expensive relative to its fundamentals. Cyclically Adjusted FCF per Share represents the company's inflation-adjusted FCF per share over a 10-year period. View historical data on Fate Therapeutics and its competitors. Fate Therapeutics's current Cyclically Adjusted FCF per Share is €-1.17. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Fate Therapeutics stock overvalued right now?
Based on GuruFocus' analysis, Fate Therapeutics (FRA:F6T) is currently considered Significantly Overvalued. The stock's GF Value™ is €0.65, compared to a current price of €2.11 — trading 224% above its estimated fair value. The current Cyclically Adjusted FCF per Share is €-1.17. Fate Therapeutics' overall GF Score™ is 33/100 with 7 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Cyclically Adjusted FCF per Share calculated?
Cyclically Adjusted FCF per Share is calculated from a company's financial statements. For Fate Therapeutics (FRA:F6T), the current Cyclically Adjusted FCF per Share is €-1.17 as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Fate Therapeutics (FRA:F6T) Overvalued in 2026?

Based on GuruFocus' analysis, Fate Therapeutics stock appears to be overvalued. The current stock price of €2.11 is trading 224% above its estimated GF Value™ of €0.65. GuruFocus considers Fate Therapeutics to be Significantly Overvalued.

Key valuation signals for FRA:F6T:

  • Cyclically Adjusted FCF per Share: €-1.17
  • GF Value™: €0.65 vs. price of €2.11 (224% above fair value)
  • GF Score™: 33/100 with 7 warning signs

No single metric tells the full story. See the FRA:F6T stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Fate Therapeutics Business Description

Other Exchanges FATE:USAF6T:Germany
Address 12278 Scripps Summit Drive, San Diego, CA, USA, 92131
Fate Therapeutics Inc is a clinical-stage biopharmaceutical company based in the United States. The company is engaged in the development of programmed cellular immunotherapies for cancer and autoimmune disorders. The company's cell therapy pipeline is comprised of NK- and T-cell immuno-oncology programs, including off-the-shelf engineered product candidates derived from clonal master iPSC lines, and immuno-regulatory programs, including product candidates to prevent life-threatening complications in patients.
33GF Score

Get the complete analysis for FRA:F6T

Cyclically Adjusted FCF per Share is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€2.11
Price
€0.65
GF Value